|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
These findings from the study demonstrated that Ras-ERK1/2 signaling could promote the development of OS via regulating H2BK12ac through MDM2-mediated CBP degradation.
|
31695502 |
2019 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results testified that Ras-ERK1/2 signalling promoted the development of OS by mediating H4K12ac through MDM2-mediated HAT1 degradation.
|
30942624 |
2019 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Circular RNA circ_0102049 promotes cell progression as ceRNA to target MDM2 via sponging miR-1304-5p in osteosarcoma.
|
31727503 |
2019 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53<sup>wt</sup> osteosarcoma cells.
|
30715803 |
2019 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We retrospectively reviewed 13 DLOS patients (six men, seven women; median age 32 years (interquartile range (IQR) 27 to 38)) diagnosed using the following criteria: the histological coexistence of low-grade and high-grade osteosarcoma components in the lesion, and positive immunohistochemistry of mouse double minute 2 homolog (MDM2) and cyclin-dependent kinase 4 (CDK4) associated with MDM2 amplification.
|
31154837 |
2019 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
These mice did not develop malignancies; however, these animals and the MG63 human osteosarcoma cell line with high levels of Mdm2 showed an increase in bone mineralization.
|
30011084 |
2018 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis.
|
30001240 |
2018 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
GRIM-19 was proved to modulate radiation-induced osteosarcoma cells apoptosis in a p53 dependent manner by mediating MDM2 activity, which sheds light on the development of GRIM-19-based molecular target therapy on osteosarcoma.
|
30005830 |
2018 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
A few cases of ESOS with MDM2 amplification have also been reported, suggesting some similarity to skeletal low-grade osteosarcoma such as parosteal osteosarcoma, where MDM2 is often amplified.
|
28235629 |
2017 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our results show that some diagnosed high-grade osteosarcomas are differentiated/dedifferentiated osteosarcomas and harbor an overexpression and amplification of MDM2.
|
26997440 |
2016 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We also observed that a dedifferentiated OS harboring MDM2 amplification did not carry any other mutations.
|
26787232 |
2016 |
|
Osteosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the present meta-analysis indicates that MDM2 rs1690916 and rs2279744 cannot be considered as genetic risk factors for OS susceptibility in the different populations.
|
27438225 |
2016 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Therefore, when compared with low-grade central and parosteal osteosarcomas, MDM2 and CDK4 markers cannot be used diagnostically to differentiate this subtype of osteosarcoma.
|
25680902 |
2015 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Using the SJSA-1 osteosarcoma cell line which harbors an amplified MDM2 gene and wild-type p53, we have investigated the acquired resistance mechanisms both in vitro and in vivo to SAR405838.
|
26070072 |
2015 |
|
Osteosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Results from this study indicated that the allele-A and genotype-AA of MDM2 c.346G>A genetic variant could be an increased risk factor for the susceptibility to osteosarcoma and might be used as a potential molecular marker for evaluating the risk of osteosarcoma.
|
25551700 |
2015 |
|
Osteosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Future studies are needed to further assess the effects of MDM2 polymorphisms on the risk and survival of osteosarcoma.
|
24122202 |
2014 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
On the other hand, late events such as the loss of RB1 and gain of MDM2, crucial regulators of cell cycle, appear to be related to the final mechanisms contributing to the metastatic establishment of osteosarcoma.
|
23845465 |
2013 |
|
Osteosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Results from this study suggest that MDM2 genetic variants are potentially related to OS susceptibility in Chinese Han population, and might be used as molecular markers for assessing OS susceptibility.
|
23933591 |
2013 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
G-banding, comparative genomic hybridization (CGH), and real-time PCR for the MDM2 and CDK4 genes were performed to describe the genetic profile of this tumor and revealed aberrations that are common findings of parosteal osteosarcomas.
|
22749040 |
2012 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We found that the HDMX-S/HDMX-FL ratio associated with common somatic genetic lesions connected with p53 inhibition, such as p53 mutation and HDM2 overexpression in osteosarcoma cell lines.
|
22700878 |
2012 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
MDM2 and CDK4 are often amplified in low-grade osteosarcomas and their dedifferentiated counterparts, and the encoded proteins are accordingly overexpressed.
|
22301501 |
2012 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
MDM2 amplification was observed in 1 of 8 osteosarcomas; 3 showed CHR12 aneusomy.
|
20881839 |
2011 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The results showed that MDM2 and/or CDK4 immunoreactivity was present in 89% of low-grade osteosarcoma specimens.
|
21336260 |
2011 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
In an effort to identify novel Mdm2 binding partners, we performed a large-scale immunoprecipitation of Mdm2 in the osteosarcoma U2OS cell line.
|
20547751 |
2010 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma.
|
20196171 |
2010 |